
AriBio has confirmed partial efficacy in the Phase 3 clinical trial for its "oral Alzheimer's drug." Based on these results, the company plans to apply for product approval from the U.S. Food and Drug Administration (FDA). Attention is now turning to whether a domestically developed new Alzheimer's drug will be born.
AriBio said Tuesday that it achieved the primary efficacy endpoint in the global Phase 3 clinical trial (POLARIS-AD) for 'AR1001' (generic name: mirodenafil), an Alzheimer's disease treatment candidate.
The company first disclosed these results at approximately 6 a.m. on the same day at the "International Conference on Alzheimer's Disease Clinical Trials" (CTAD 2026) held in Boston, U.S. Professor Sharon Sha, head of the memory disorders division at Stanford University and the overall principal investigator for the AR1001 global clinical trial, delivered the presentation.
The global Phase 3 trial for AR1001 was conducted on 1,535 patients with early-stage Alzheimer's disease across approximately 230 clinical sites in 13 countries. Participating patients took one pill per day of either 30 milligrams (mg) of AR1001 or a placebo for 52 weeks and underwent regular clinical evaluations.
AriBio explained that the Phase 3 trial for AR1001 was designed to be evaluated separately in two pre-specified primary analysis populations: the overall population (1,535 patients) and the monotherapy population (604 patients). The company stated that the primary endpoint is considered achieved if a statistically significant difference compared to the placebo is observed in at least one of these groups.
The primary endpoint for the Phase 3 trial of AR1001 is the change from baseline in the "Clinical Dementia Rating Sum of Boxes" (CDR-SB) score at Week 52. This is a metric that comprehensively measures memory and activities of daily living.
According to the Phase 3 analysis results for AR1001, the rate of clinical disease progression in the monotherapy group was 31% slower in the treatment group compared to the placebo group. The CDR-SB score in the treatment group was 0.44 points lower than in the placebo group, confirming less symptom deterioration. The company explained that this result possessed statistical significance (p-value = 0.0266). The disease progression delay effect, converted into time, is 3.5 months for the monotherapy group.
However, in the overall population, the difference in CDR-SB scores between the AR1001 treatment group and the placebo group was recorded as 11 points (p-value = 0.4015). While numerically favorable to the AR1001 treatment group, statistical significance was not demonstrated.
The safety assessment of the Phase 3 trial for AR1001 confirmed relatively good tolerability. The incidence of adverse reactions occurring after administration of AR1001 was 69% in the treatment group and 66.4% in the placebo group. Most were mild or moderate. The incidence of serious adverse reactions was similar, at 10% in the treatment group and 9.8% in the placebo group.
Based on this data, AriBio evaluated that the global Phase 3 trial for AR1001 was successful. The company plans to actively proceed with additional analyses and consultations with global regulatory authorities based on the efficacy results of the monotherapy group confirmed in the clinical trial. How regulatory agencies such as the U.S. FDA will evaluate the Phase 3 data for AR1001 remains a variable for new drug product approval.
If AriBio's AR1001 obtains product approval, it could position itself as the world's first oral (taken by mouth) Alzheimer's treatment. The current global Alzheimer's treatment market is dominated by injectable drugs such as "Leqembi." Analysts assess that the unique convenience of an oral medication can be evaluated as a differentiated competitive advantage in the Alzheimer's treatment market.
The company collaborated with China's Fosun Pharma during the completion of the global Phase 3 trial for AR1001. In May, it signed a global rights agreement worth a total of $4.7 billion (approximately 7 trillion won at the exchange rate at the time) with Fosun Pharma. Following this, in July, AriBio concluded a strategic equity investment contract with Fosun Pharma.
AriBio CEO Chung Jae-jun said, "We began developing AR1001 with the goal of creating an oral treatment that slows the progression of Alzheimer's disease and can be conveniently used for long periods by patients and caregivers."
He added, "AriBio's vision is to provide patients and families with broader treatment options through an oral medication taken once a day, and we will quickly proceed to file for FDA approval based on the global clinical trial results."